A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Checked against the public recordLast updated Aug 28, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Genentech, Inc.
- Interventions being studied
- Drug: GDC-6036; Drug: Atezolizumab; Drug: Cetuximab; Drug: Bevacizumab; Drug: Erlotinib; Drug: GDC-1971; Drug: Inavolisib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation. * Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol. * Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol. Exclusion Criteria: * Active brain metastases. * Malabsorption or other condition that interferes with enteral absorption. * Clinically significant cardiovascular dysfunction or liver disease.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- City of Hope Comprehensive Cancer CenterDuarte, California
- UCSD Moores Cancer CenterLa Jolla, California
- Chao Family Comprehensive Cancer Center UCIOrange, California
- Yale Cancer CenterNew Haven, Connecticut
- Florida Cancer Specialists - SarasotaSarasota, Florida
- Dana Farber Cancer InstituteBoston, Massachusetts
- Memorial Sloan Kettering Cancer CenterNew York, New York
- University of OklahomaOklahoma City, Oklahoma
- UPMC - Hillman Cancer CenterPittsburgh, Pennsylvania
- Slade Health Inward goodsMount Kuring-Gai, New South Wales
- Peter MacCallum Cancer CenterMelbourne, Victoria
- Alfred HealthMelbourne, Victoria
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 28, 2026. Always confirm current availability with the study team.